BTIG analyst Ryan Zimmerman upgraded AxoGen to Buy with a price target of $28, citing the stabilizing of its sales force based on his analysis of LinkedIn data and expectations that the management will have learned from its past mistakes by offering a more conservative guidance. The analyst also believes that AxoGen could become an M&A target since its potential acquirers have improved leverage ratios and have discussed deploying capital. Moreover, Zimmerman anticipates AxoGen's Avance nerve graft platform to be granted a Biologics License Application status by the FDA, but even in its absence, the analyst contends the company "isn't limited from selling Avance under 361 HCT/P," or Human cells, tissues, or cellular or tissue-based products regulations.